Comparison · NCT02216123-3fe89e35
TQ+CQ vs PQ+CQ: Number of Participants With P. Falciparum
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. TQ+CQ vs PQ+CQ: Number of Participants With P. Falciparum. Trial comparisons, record NCT02216123-3fe89e35. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02216123-3fe89e35
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0241 | 0.00941 | 0.0603 | wilson | |
| Risk in group 2 | 0.0353 | 0.0121 | 0.0987 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0112 | -0.0763 | 0.0318 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.683 | 0.156 | 2.98 | log | |
| Odds ratio, group 1 over group 2 | 0.675 | 0.148 | 3.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on TQ+CQ than on PQ+CQ | 89.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | TQ+CQ | Participants were administered CQ 600 milligram (mg) once daily on Days 1 and 2 and CQ 300 mg on Day 3. A single dose of TQ 300 mg was administered orally on Day 1 or Day 2. PQ placebo capsules were administered orally once daily for 14 days starting on the same day as TQ administration. | 4 | 166 | OG000 |
| Group 2 | PQ+CQ | Participants were administered CQ 600 mg tablet once daily on Days 1 and 2 and CQ 300 mg on Day 3. Participants received a single TQ placebo tablet orally on Day 1 or Day 2. PQ 15 mg was administered orally once daily for 14 days starting on the same day as TQ placebo administration. | 3 | 85 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With P. Falciparum
- Description
Microscopic blood slides (two thick film and one thin film slide) were prepared and examined for asexual parasite count. The number of participants with positive P. falciparum asexual parasite count post Baseline has been summarized for each treatment arm.
- Time frame
- Up to Day 180
- Population
- mITT Population
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
- NCT number
- NCT02216123
- Phases
- PHASE3
- Conditions
- Malaria, Vivax
- Interventions
- Tafenoquine, Tafenoquine Placebo, Chloroquine, Primaquine, Primaquine Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2018-05-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02216123?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02216123-3fe89e35